Takara Bio Inc. announced that it entered into an agreement with Cellectis SA (“CSA” Head office, France) regarding 100% share acquisition of Cellectis AB (“CAB”, Head office, Sweden), a firm conducting stem cell business of CSA. The acquisition will be completed in December, 2014.

 

CAB was established following the purchase by CSA of Cellartis in 2011, and provides technologies for inducing differentiation of iPS and other stem cells into several types of cells including liver cells and pancreatic cells, and provides products related to stem cells, including ES, iPS and differentiated cells. The company’s products are in wide use throughout the world in the fields of regenerative medicine research and evaluation of candidate substances of medicines.

 

Takara Bio acquires technology of inducing differentiation, which enhances its technology base. Takara Bio sales initiatives involve expanding lineup of products and our business results in bioindustry business.

 

This acquisition has only slight effect on estimated consolidated and non-consolidated operating results of the fiscal year ended March 2015.

【Profile of CAB】

Name Cellectis AB
Established 2011 (original company, Cellartis was established in 2001)
Head Office Arvid Wallgrens Backe 20, 41346, Göteborg, Sweden
Business Manufacturing and marketing of stem cell relating products

Number of employees

 42 (As of July 2014)

【Profile of CSA】

Name Cellectis SA
Established 1999
Capital 1,054,000 euro (As of December 31, 2013)
Representative André Choullika (Chairman and Chief Executive Officer)
Head office 8 rue de la Croix Jarry 75013 Paris, France
Business Biopharmaceuticals foucsed on oncology. Three mainstays are research support service, medicine, and plant science. CSA is listed on NYSE Alternext.
Consolidated sales 16,523,000 euro (January to December, 2013)
Number of employees 228 (as of December 31, 2012)